- Home
- NHS vs OBIO Comparison
NHS vs OBIO Comparison
Compare NHS & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- OBIO
- Stock Information
- Founded
- NHS 2003
- OBIO 2017
- Country
- NHS United States
- OBIO United States
- Employees
- NHS N/A
- OBIO N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- NHS Finance
- OBIO Health Care
- Exchange
- NHS Nasdaq
- OBIO Nasdaq
- Market Cap
- NHS 213.4M
- OBIO 200.1M
- IPO Year
- NHS N/A
- OBIO N/A
- Fundamental
- Price
- NHS $7.65
- OBIO $5.28
- Analyst Decision
- NHS
- OBIO Strong Buy
- Analyst Count
- NHS 0
- OBIO 4
- Target Price
- NHS N/A
- OBIO $15.75
- AVG Volume (30 Days)
- NHS 111.8K
- OBIO 60.4K
- Earning Date
- NHS 01-01-0001
- OBIO 11-12-2024
- Dividend Yield
- NHS 13.44%
- OBIO N/A
- EPS Growth
- NHS N/A
- OBIO N/A
- EPS
- NHS N/A
- OBIO N/A
- Revenue
- NHS N/A
- OBIO $2,647,000.00
- Revenue This Year
- NHS N/A
- OBIO $7.68
- Revenue Next Year
- NHS N/A
- OBIO $110.40
- P/E Ratio
- NHS N/A
- OBIO N/A
- Revenue Growth
- NHS N/A
- OBIO N/A
- 52 Week Low
- NHS $6.95
- OBIO $4.22
- 52 Week High
- NHS $9.17
- OBIO $11.69
- Technical
- Relative Strength Index (RSI)
- NHS 27.55
- OBIO 43.96
- Support Level
- NHS $7.96
- OBIO $5.01
- Resistance Level
- NHS $8.16
- OBIO $6.50
- Average True Range (ATR)
- NHS 0.13
- OBIO 0.49
- MACD
- NHS -0.04
- OBIO -0.09
- Stochastic Oscillator
- NHS 0.94
- OBIO 19.74
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.